Difference between revisions of "Ipilimumab (Yervoy)"
m |
|||
| Line 22: | Line 22: | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
| − | [[Category:Anti- | + | [[Category:Anti-CTLA-4 medications]] |
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
Revision as of 14:56, 6 September 2014
General information
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Ipilimumab (Yervoy) package insert PDF pages 6-7[1]
- Ipilimumab (Yervoy) patient drug information (Chemocare)[5]
- Ipilimumab (Yervoy) patient drug information (UpToDate)[6]
Also known as
BMS-734016 or MDX-010.
References
- ↑ 1.0 1.1 1.2 Ipilimumab (Yervoy) package insert
- ↑ Ipilimumab (Yervoy) package insert (locally hosted backup)
- ↑ Yervoy manufacturer's website
- ↑ YERVOY Risk Evaluation and Mitigation Strategy (REMS) Site
- ↑ Ipilimumab (Yervoy) patient drug information (Chemocare)
- ↑ Ipilimumab (Yervoy) patient drug information (UpToDate)